Get the Stockscreener App
11.09
7.06%
0.77
Erasca Inc stock is traded at $11.09, with a volume of 5.09M.
It is up +7.06% in the last 24 hours and down -49.11% over the past month.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.
See More
Previous Close:
$10.32
Open:
$10.38
24h Volume:
5.09M
Relative Volume:
0.80
Market Cap:
$3.46B
Revenue:
-
Net Income/Loss:
$-124.55M
P/E Ratio:
-25.24
EPS:
-0.4393
Net Cash Flow:
$-95.58M
1W Performance:
+5.62%
1M Performance:
-49.11%
6M Performance:
+297.42%
1Y Performance:
+763.14%
1-Day Range:
$10.38
$11.44
1-Week Range:
$9.80
$11.44
52-Week Range:
$1.06
$24.28
Erasca Inc Stock (ERAS) Company Profile
Name
Erasca Inc
Sector
Industry
Phone
(858) 465-6511
Address
3115 MERRYFIELD ROW, SAN DIEGO
Compare ERAS vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ERAS
Erasca Inc
|
11.11 | 3.19B | 0 | -124.55M | -95.58M | -0.4393 |
VRTX
Vertex Pharmaceuticals Inc
|
429.96 | 110.81B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
646.97 | 66.02B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
804.52 | 48.27B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.53 | 38.22B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.16 | 30.69B | 742.00K | -1.37B | -1.07B | -7.0731 |
Erasca Inc Stock (ERAS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-27-26 | Resumed | Mizuho | Outperform |
| Jan-07-26 | Initiated | Piper Sandler | Overweight |
| Oct-16-25 | Initiated | Stifel | Buy |
| Sep-03-25 | Downgrade | BofA Securities | Buy → Underperform |
| Aug-18-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-26-25 | Initiated | Raymond James | Outperform |
| Nov-18-24 | Initiated | Jefferies | Buy |
| Mar-11-24 | Initiated | CapitalOne | Overweight |
| Jan-05-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-11-23 | Initiated | H.C. Wainwright | Buy |
| Mar-30-23 | Initiated | Mizuho | Buy |
| Feb-24-23 | Initiated | Goldman | Buy |
| Feb-03-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Erasca Inc Stock (ERAS) Latest News
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Erasca, Inc. (ERAS) And Encourages Shareholders to Reach Out - ACCESS Newswire
ERAS INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Erasca, Inc. - Business Wire
ERASCA INVESTOR ALERT: Bragar Eagel & Squire, P.C. is Investigating Erasca, Inc. on Behalf ... - Caledonian Record
ERASCA INVESTOR ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
ERASCA INVESTOR ALERT: Bragar Eagel & Squire, P.C. is Investigating Erasca, Inc. on Behalf of Erasca Stockholders and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc.ERAS - FinancialContent
Erasca, Inc. (ERAS) Shares Crater 48%, Wiping Out $2.8 - GlobeNewswire
Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More - AOL.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Erasca, Inc. (ERAS) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Erasca : Corporate Presentation May 2026 - marketscreener.com
Biotech Fund Sells $44.5 Million Erasca Stake After Massive 700% Rally - The Motley Fool
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc.ERAS - ACCESS Newswire
Cormorant Asset Management Takes New Stake in Erasca – Filing Reveals $93.84M PositionNews and Statistics - IndexBox
Cormorant Asset Management Acquires Erasca Shares - Intellectia AI
Erasca, Inc.Common Stock (NQ: ERAS - FinancialContent
Erasca Touts 'Eye-Popping' ERAS-0015 Lung Cancer Data, FDA Path at BofA Conference - Yahoo Finance
Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buy - sharewise.com
Erasca Inc stock (US29479V1044): cancer drug developer in focus after recent trial and financing upd - AD HOC NEWS
Erasca (NASDAQ:ERAS) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
Erasca (NASDAQ: ERAS) foundation reports three 8,333‑share sales in Form 144 - Stock Titan
Venrock entities report 16.38M shares in Erasca (NASDAQ: ERAS) amendment - Stock Titan
Paradigm BioCapital reports 10.4M-share stake in Erasca (NASDAQ: ERAS) - Stock Titan
T. Rowe Price holds 21.2M Erasca shares (ERAS) as 6.8% owner - Stock Titan
RTW Funds, Roderick Wong report 5.2% stake in Erasca (ERAS) - Stock Titan
Erasca, Inc. (ERAS) Investigation: Bronstein, Gewirtz & Grossman - The National Law Review
Erasca shares plunge 48% after patent infringement and trade secret claims surface. - Pluang
TNGX stock hits record high on inking collaboration deal with ERAS - MSN
ERAS SHAREHOLDER ALERT: Investors Encouraged to Contact - GlobeNewswire
Erasca stock plunges 48% after patent infringement and trade secret claims trigger investigation. - Pluang
Erasca Inc stock (US29479V1044): Q1 loss widens on ERAS-0015 deal as Merck alliance sharpens oncolog - AD HOC NEWS
Why This Hedge Fund Added $29 Million to a Cancer Stock Already Up 700% - The Globe and Mail
Here's Why We're Watching Erasca's (NASDAQ:ERAS) Cash Burn Situation - Moomoo
The Bull Case For Erasca (ERAS) Could Change Following New KEYTRUDA Alliance And ERAS-0015 Focus Shift - simplywall.st
Bronstein, Gewirtz & Grossman, LLC Is Investigating Erasca, Inc. (ERAS) And Encourages Investors to Connect - The National Law Review
Analysts Offer Insights on Healthcare Companies: Erasca (ERAS), Canopy Growth (CGC) and Alkermes (ALKS) - The Globe and Mail
ERASCA, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud - The National Law Review
H.C. Wainwright Maintains Erasca(ERAS.US) With Buy Rating, Maintains Target Price $20 - Moomoo
[SCHEDULE 13G/A] Erasca, Inc. Amended Passive Investment Disclosure - Stock Titan
Stifel Maintains Erasca(ERAS.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Erasca stock (US29479V1044): Q1 2026 cash runway extends to H2 2028 after equity raise - AD HOC NEWS
Bronstein, Gewirtz & Grossman, LLC Encourages Erasca, Inc. (ERAS) - The National Law Review
Erasca Releases Q1 2026 Financial Results - AlphaStreet
A Quick Look at Today's Ratings for Erasca(ERAS.US), With a Forecast Between $9 to $30 - Moomoo
Mizuho cuts Erasca stock price target on acquisition payment - Investing.com UK
How Investors Are Reacting To Erasca (ERAS) Wider Losses And Early Oncology Pipeline Efficacy Signs - Yahoo Finance
Erasca partners with Merck on best-in-class pan-RAS molecular glue - The Pharma Letter
Mizuho cuts Erasca stock price target on acquisition payment By Investing.com - Investing.com South Africa
TradingKey - TradingKey
Erasca stock jumps on Merck cancer drug trial collaboration - Investing.com
Erasca: 'Hold' On Substantial RAS Targeting ERAS-0015 But With Two Key Risks - Seeking Alpha
Erasca Inc Stock (ERAS) Financials Data
Revenue
Net Income
Cash Flow
EPS
10.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):